Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
Jakob Schöttle(University of Cologne), Roland T. Ullrich(University of Cologne)
Cited by 21
Related Papers
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
|Proceedings of the National Academy of Sciences|2009|255
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
|Journal of Clinical Investigation|2013|193
Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)
|PLoS ONE|2008|91